We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Cardiology

Rethinking Race/Ethnicity in Cardiovascular Risk Assessment: The Race-Free MESA Risk Score

MedXY Editorial Team•Aug 7, 2026•Cardiology
cardiovascular riskMESA scoreRace/ethnicityCoronary heart disease

Highlight

1. The original MESA risk score includes race/ethnicity as a predictor for coronary heart disease risk alongside coronary artery calcium and traditional cardiovascular risk factors.
2. A newly developed race-free MESA risk score eliminates race/ethnicity but retains several novel interaction terms, maintaining predictive performance.
3. The race-free score shows comparable discrimination and calibration to the original, with no significant difference in predictive accuracy.
4. This suggests that race/ethnicity may be excluded from risk models without loss of clinical utility, addressing concerns about race-based risk stratification.

Study Background

Cardiovascular disease remains a leading cause of morbidity and mortality globally, necessitating precise risk stratification tools for prevention and management. The Multi-Ethnic Study of Atherosclerosis (MESA) risk score is widely used to estimate the 10-year risk of coronary heart disease (CHD). A key feature of the original MESA score was the inclusion of coronary artery calcium (CAC) scoring alongside traditional cardiovascular risk factors and race/ethnicity categories (White, Hispanic/Latino, Black, Chinese). However, the use of race/ethnicity in clinical algorithms has raised ethical and methodological concerns, including potential reinforcement of health disparities and limited biological basis of racial categories.

Study Design

This study reanalyzed data from the MESA cohort, which enrolls community-based adults aged 45 to 84 years without prevalent cardiovascular disease. The authors developed a race-free MESA risk model by adopting the original two-step regression approach: first applying least absolute shrinkage and selection operator (LASSO) regression for variable selection, followed by ridge regression to reduce overfitting. Importantly, race/ethnicity variables and any interaction terms involving them were excluded as candidate predictors, allowing evaluation of model performance without racial classification.

Key Findings

The race-free MESA risk score retained some interaction terms that were not part of the original score, indicating that other variables and their interactions may compensate for the predictive contribution previously attributed to race/ethnicity.

Performance metrics showed that the area under the receiver operating characteristic curve (AUC) for the race-free model was 0.820 (95% CI, 0.801-0.840), very close to that of the original model. The difference in AUC was 0.0032 (95% CI, -0.0008 to 0.0073), not statistically significant, supporting comparable discrimination between models.

The discrimination slope, a measure of risk stratification, was slightly improved in the race-free score (0.101) compared to the original (0.0937), suggesting enhanced separation between events and nonevents.

Both models demonstrated good calibration, indicating accurate prediction of observed event rates across risk strata.

Expert Commentary

The findings underscore the potential to remove race/ethnicity from cardiovascular risk prediction algorithms without compromising clinical accuracy. This aligns with evolving recommendations discouraging routine use of race in clinical algorithms due to concerns about perpetuating disparities and the social construct nature of race.

The maintenance of predictive accuracy after excluding race suggests that the underlying clinical and imaging variables, along with nuanced interactions, can adequately capture relevant risk factors typically correlated with race/ethnic categories.

However, limitations include the focus on four specific racial/ethnic groups from the original MESA cohort and potential differences in phenotypic risk heterogeneity not fully captured in nonracial variables. Further validation in diverse external populations is warranted.

Conclusion

This study provides important evidence supporting a race-free MESA coronary heart disease risk score with similar predictive performance to the original model. Removing race/ethnicity from prediction models may promote equity in cardiovascular risk assessment and guide clinical decision-making without reinforcing race-based categorizations.

Future research should focus on external validation, assessment of clinical impact in diverse populations, and exploration of alternative social and environmental determinants of cardiovascular risk to enhance individualized prediction.

Funding and ClinicalTrials.gov

The study was supported by data from the Multi-Ethnic Study of Atherosclerosis cohort. Specific funding sources for this secondary analysis were not detailed. ClinicalTrials.gov registration details for the original MESA cohort are available (NCT00005487).

References

White Q, Hansen S, Murphy BS, Johnson C, DeFilippis A, Post W, McClelland R. Reevaluating the Use of Race/Ethnicity in the MESA Risk Score. J Am Heart Assoc. 2026 Jul 7;15(13):e047013. doi: 10.1161/JAHA.125.047013. Epub 2026 Jul 3. PMID: 42396766.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Genetically Mediated LDL Cholesterol Variations and Their Limited Impact on Venous Thromboembolism RiskThis study reveals that lifelong genetic differences in LDL cholesterol levels do not significantly affect the risk of venous thromboembolism (VTE), suggesting LDL-C may not be a major causal factor in VTE development.Sep 25, 2026Enhancing Prognosis in Stable Coronary Artery Disease: Insights from a Nationwide Cohort on FFR-CTThis large nationwide study demonstrates that coronary CTA-derived FFR-CT strongly predicts future myocardial infarction, cardiovascular death, and revascularization, independent of traditional risk factors and stenosis severity, with a thrSep 25, 2026Unexpected Early Postoperative Lipid Deterioration in Cushing’s Syndrome: Implications for Cardiovascular Risk and ManagementThis study reveals that lipid profiles paradoxically worsen during the early remission phase after curative surgery for Cushing’s syndrome, highlighting a critical window for cardiovascular risk and targeted intervention.Sep 22, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Efficacy and Safety of Low-Dose Rivaroxaban in Advanced Chronic Kidney Disease with High Cardiovascular Risk: A Comprehensive Review
Low-dose rivaroxaban failed to reduce cardiovascular events but increased major bleeding in advanced CKD patients at high cardiovascular risk, underscoring the need for cautious anticoagulant use.
Sep 21, 2026
A Synopsis of the 2025 VA/DoD Lipid Management Guideline: What Clinicians Need to KnowConcise review of the 2025 VA/DoD lipid guideline: new risk tool (PREVENT), CAC and one-time Lp(a) for risk refinement, statins for selected primary prevention groups (including people with HIV), and intensified combination therapy for verySep 19, 2026
Subclinical Liver Disease as a Silent Driver of Cardiovascular Risk: Insights from a Large-Scale Prospective StudySubclinical liver disease, marked by steatosis, fibrosis, and functional impairment, independently and synergistically increases cardiovascular disease risk. Incorporating non-invasive liver biomarkers could enhance CVD risk prediction andSep 15, 2026